Takeda Pharmaceutical Company Limited
Organization details
- Legal name
- Takeda Pharmaceutical Company Limited
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Headquarters city
- Tokyo
- Headquarters country
- Japan
- Ticker symbol
- TAK
- Primary stock exchange
- NYSE
Identifiers
- SEC CIK
- 0001395064
Board of directors
-
Andrew Stewart Plump · Director · President, R&DSince 2026
-
Bruce D. Broussard · DirectorSince 2026
-
Christophe Pierre Weber · Director · President and CEOSince 2026
-
Emiko Higashi · DirectorSince 2026
- Since 2026
-
Jean Luc Butel · DirectorSince 2026
- Since 2026
-
Julie So-Young Kim · Director · President and CEOSince 2026
-
Kimberly A. Reed · DirectorSince 2026
-
Koichiro Kimura · DirectorSince 2026
-
Koji Hatsukawa · DirectorSince 2026
-
Masami Iijima · DirectorSince 2026
-
Michel Bruno Orsinger · DirectorSince 2026
-
Miki Tsusaka · DirectorSince 2026
-
Milano Furuta · Director · Chief Financial OfficerSince 2026
-
Paulus Stoffels · DirectorSince 2026
-
Steven Gillis · DirectorSince 2026
-
Yoshiaki Fujimori · DirectorSince 2026
Chief executives
Board connections
9 of this board's directors also sit on 26 other boards. 17 are in the same sector.
-
Boston Scientific Corporation Same sectorvia Christophe Pierre Weber and Yoshiaki Fujimori
-
Agios Pharmaceuticals Inc. Same sectorvia John Maraganore
-
Beam Therapeutics Inc. Same sectorvia John Maraganore
-
BioMarin Pharmaceutical Inc. Same sectorvia Ian T. Clark
- via Yoshiaki Fujimori
-
City Therapeutics Inc. Same sectorvia John Maraganore
-
Corvus Pharmaceuticals Inc. Same sectorvia Ian T. Clark
- via Ian T. Clark
-
Guardant Health Inc. Same sectorvia Ian T. Clark
- via Kimberly A. Reed
- via Bruce D. Broussard
-
Hemab Therapeutics Holdings Inc. Same sectorvia John Maraganore
- via Bruce D. Broussard
- via Emiko Higashi
-
Kardigan Inc. Same sectorvia Steven Gillis
-
Kymera Therapeutics Inc. Same sectorvia John Maraganore
-
Kyverna Therapeutics Inc. Same sectorvia Ian T. Clark
- via Bruce D. Broussard
- via Kimberly A. Reed
-
Olema Pharmaceuticals Inc. Same sectorvia Ian T. Clark
-
ProKidney Corp. Same sectorvia John Maraganore
-
Q32 Bio Inc. Same sectorvia Steven Gillis
- via Emiko Higashi
-
Rani Therapeutics Holdings Inc. Same sectorvia Jean Luc Butel
-
Rapport Therapeutics Inc. Same sectorvia John Maraganore
-
Tectonic Therapeutic Inc. Same sectorvia Ian T. Clark
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $15,224,704
- 22 sales by 13 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Nov 4, 2026 | Platford Giles Richard Officer (President, IBU) | Open-market sale | −55,617 | $20.90 | $1,162,395 |
| Nov 2, 2026 | Teresa Marie Bitetti Officer (President, OBU) | Open-market sale | −46,609 | $20.89 | $973,662 |
| Sep 14, 2026 | Duprey Lauren Rusckowski Officer (Chief Transformation Officer) | Open-market sale | −34,535 | $18.54 | $640,279 |
| Sep 2, 2026 | Andrew Stewart Plump Director, Officer (President, R&D) | Open-market sale | −116,191 | $18.49 | $2,148,372 |
| Aug 19, 2026 | Andrew Stewart Plump Director, Officer (President, R&D) | Open-market sale | −19,651 | $18.49 | $363,347 |
| Aug 18, 2026 | Greenway Nicola Deidre Petal Officer (Chief Human Resources Officer) | Open-market sale | −12,980 | $18.11 | $235,068 |
| Aug 11, 2026 | Shannon Elaine Mary Officer (Pres., Global Supply & Quality) | Open-market sale | −20,363 | $17.55 | $357,371 |
| Aug 10, 2026 | Teresa Marie Bitetti Officer (President, OBU) | Open-market sale | −50,012 | $17.10 | $855,205 |
| Aug 10, 2026 | Duprey Lauren Rusckowski Officer (Chief Transformation Officer) | Open-market sale | −47,586 | $17.10 | $813,721 |
| Aug 10, 2026 | Farajallah Awny Samaan Botros Officer (Chief Medical Officer) | Open-market sale | −14,006 | $17.10 | $239,503 |
| Aug 10, 2026 | Furney Natalie Anne Marie Officer (Global General Counsel) | Open-market sale | −30,868 | $17.10 | $527,843 |
| Aug 10, 2026 | Greenway Nicola Deidre Petal Officer (Chief Human Resources Officer) | Open-market sale | −975 | $17.50 | $17,063 |
| Aug 10, 2026 | Greenway Nicola Deidre Petal Officer (Chief Human Resources Officer) | Open-market sale | −6,774 | $17.10 | $115,835 |
| Aug 10, 2026 | Ibrahim Ramy Riad Ahmed Officer (President, PDT BU) | Open-market sale | −7,277 | $17.10 | $124,437 |
| Aug 10, 2026 | Julie So-Young Kim Director, Officer (President and CEO) | Open-market sale | −89,090 | $17.10 | $1,523,439 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Takeda Pharmaceutical Company Limited
Who is the CEO of Takeda Pharmaceutical Company Limited?
Christophe Pierre Weber has been Takeda Pharmaceutical Company Limited's President and CEO since March 2026.
How many directors are on Takeda Pharmaceutical Company Limited's board?
Takeda Pharmaceutical Company Limited's board has 18 directors: Andrew Stewart Plump, Bruce D. Broussard, Christophe Pierre Weber, Emiko Higashi, Ian T. Clark, Jean Luc Butel, John Maraganore, Julie So-Young Kim, Kimberly A. Reed, Koichiro Kimura and 8 others.
Are Takeda Pharmaceutical Company Limited insiders buying or selling shares?
Over the last 12 months, Takeda Pharmaceutical Company Limited insiders made no open-market purchases and sold $15.2 million of shares in 22 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="takeda-pharmaceutical-company-limited"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.